Going after the viral achilles' heel

G.ST Antivirals is a clinical-stage biotech company that applies an innovative host cell-based strategy to develop broad-spectrum antivirals against infections of the respiratory tract.

Our mission

Treatments against the vast majority of viruses are scarce, and often leave physicians empty handed when dealing with viral infections.

G.ST Antivirals is determined to apply its innovative host cell-based strategy to develop broad-spectrum antivirals against infections of the respiratory tract such as the common cold. 

Laxmikant Wali and Vitalii Kovtunyk at work


Where we come from

Publishing a high-impact paper on the interaction of a respiratory virus with the infected cell, the founders Guido Gualdoni and Johannes Stöckl recognized the therapeutic potential of manipulating the metabolism of the host cell to overcome respiratory viral infections. This led to the establishment of a highly innovative, patented medication against rhinoviruses, the causative agent of the common cold and more severe respiratory diseases in vulnerable individuals.

As a result, G.ST Antivirals was founded in 2019 as a spin-off of the Medical University of Vienna, to exploit these academic findings and develop therapeutics for the benefit of patients.

Delyana Stoeva at work



Viruses do not possess a metabolism of their own and are therefore entirely dependent on the host cell to provide the nutrient supply, e.g., of sugar, they need for replication. The founders of G.ST Antivirals performed pioneering scientific work uncovering specific viral dependencies on host cell metabolic pathways in the field of respiratory viruses. They further discovered that blocking the viruses’ access to nutrients results in their starvation within the host cell and therefore a complete elimination of viral reproduction. 

G.ST Antivirals’ unprecedented approach to treat viral infections is not only highly effective, but also unsusceptible to resistance development. 

Scharon Chou at work


The first product of G.ST Antiviral’s pipeline is 2-deoxyglucose (2-DG) against rhinovirus infections. This respiratory pathogen causes highly abundant diseases such as the common cold, but also more severe diseases of the respiratory system such as asthma and COPD exacerbations. 

G.ST Antivirals' proprietary 2-DG containing nasal spray is currently undergoing Phase 1 testing at the Vienna General Hospital, Austria.

Vitalii Kovtunyk at work


G.ST Antivirals nominated among the top 10 for the Bridging Science& Business Award of the Rudolf Sallinger Foundation

G.ST Antivirals reaches a major milestone in the development of its lead asset and begins clinical phase I at the Vienna General Hospital

G.ST Antivirals to expand its innovative host cell-based treatment approach to COPD exacerbations after succeeding in highly competitive Life science call of the Vienna Business Agency



Medical University of Vienna logoFFG Promoting Innovation. logoAustria Wirtschaftsservice logoWirtschaftsagentur Stadt Wien logo


IST cube logoSchütz Family Office logo